November 11, 2020

BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine

Vancouver, BC, Nov 11, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (“BioVaxys”) is pleased to announce that results from its…